Roche’s ipatasertib in combination with Tecentriq and chemotherapy shows promising anti-tumour activity in triple-negative breast cancer in early phase trial

Roche (SIX: RO, ROG; OTCQX: RHHBY) will present the initial results from a Phase Ib study evaluating the efficacy and safety for the combination of…

View More Roche’s ipatasertib in combination with Tecentriq and chemotherapy shows promising anti-tumour activity in triple-negative breast cancer in early phase trial

Janssen Submits Supplemental New Drug Application to U.S. FDA for INVOKANA®(canagliflozin) for the Treatment of Chronic Kidney Disease in Patients with Type 2 Diabetes

The Janssen Pharmaceutical Companies of Johnson & Johnson announced  the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration…

View More Janssen Submits Supplemental New Drug Application to U.S. FDA for INVOKANA®(canagliflozin) for the Treatment of Chronic Kidney Disease in Patients with Type 2 Diabetes